Skip to main content

Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping with Hodgkin Lymphoma

Trial Status: Active

This trial studies how well a mind-body intervention works in improving overall quality of life in adolescents and young adults with Hodgkin lymphoma. A meditation based mind-body intervention may help lower distress, depressive symptoms, and anxiety in adolescents and young adults coping with Hodgkin lymphoma.

Inclusion Criteria

  • Participants diagnosed within 6 months with stage I-IV HL
  • Eastern Cooperative Oncology Group (ECOG) performance status of 2 or below
  • Having access to the internet
  • Able to read, write and speak English

Exclusion Criteria

  • Major psychiatric or cognitive deficits that would impede the completion of self-report instruments as deemed by the clinical team
  • Regular (self-defined) participation in psychotherapy or a formal cancer support group

Texas

Houston
M D Anderson Cancer Center
Status: ACTIVE
Contact: Kathrin Milbury
Phone: 713-745-2868

PRIMARY OBJECTIVE:

I. Examine the feasibility of the mind-body intervention in adolescents and young adults (AYAs) with Hodgkin lymphoma (HL).

SECONDARY OBJECTIVE:

I. Establish the initial intervention efficacy regarding psychological distress and cancer symptoms (tertiary objective) relative to an attention control (AC) group.

EXPLORATORY OBJECTIVE:

I. Explore mediation (e.g., mindfulness, compassion, social connection, inflammatory processes) and moderation (e.g., demographic and medical factors) of the intervention effects.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients attend meditation group sessions over 75 minutes once weekly for up to 5 weeks.

GROUP II: Patients attend educational group sessions over 75 minutes once weekly for up to 5 weeks.

After completion of study intervention, patients are followed at 6 and 12 weeks.

Trial Phase Phase NA

Trial Type Supportive care

Lead Organization
M D Anderson Cancer Center

Principal Investigator
Kathrin Milbury

  • Primary ID 2019-0282
  • Secondary IDs NCI-2019-05846
  • Clinicaltrials.gov ID NCT04270266